Company news
Immutep Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Immutep secures commitments for A$60 million in a Placement
June 20, 2021
Immutep global webcast slides
June 9, 2021
Immutep Reveals a New anti-LAG-3 Research Program
June 7, 2021
Immutep Reports Positive Data from its TACTI-002 ph 2 trial
June 4, 2021
Immutep granted European patent for its LAG-3 candidate Efti
June 2, 2021
Immutep enters New Collaboration with Merck KGaA for Efti
May 31, 2021
Immutep granted Chinese patent for its LAG-3 candidate Efti
May 26, 2021
Operational Update
May 7, 2021
TACTI-002 & INSIGHT-004 data to be presented at ASCO
April 28, 2021
Immutep receives A$1,155,055 R&D Tax Incentive
April 16, 2021
Immutep achieves Fast Track designation for Efti from US FDA
April 7, 2021
Immutep announces European Patent Grant for LAG525
April 6, 2021
Immutep collaborates with MSD for phase 2b head & neck trial
March 15, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Immutep secures second US patent grant for eftilagimod alpha
March 9, 2021
Phase II study for eftilagimod alpha in COVID-19 advances
January 26, 2021
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
January 21, 2021
Recruitment of head & neck cancer patients completed for ph2
January 6, 2021
Immutep granted US patent for eftilagimod alpha with a PD-1
December 29, 2020
Immutep Upscales Efti Manufacturing
December 16, 2020
Immuteps partner EOC pharma to start Ph II trial in MBC
December 9, 2020
Proposed issue of Securities - IMM
November 18, 2020
Pause in Trading
November 17, 2020
Encouraging Phase II TACTI-002 data reported at SITC 2020
November 9, 2020
Immutep Announces Australian Patent Grant for IMP701
November 8, 2020
Immutep enters into a Licence & Collaboration with LabCorp
October 29, 2020
2020 AGM Presentation
October 26, 2020
COVID-19 phase 2 investigator initiated trial commences
October 22, 2020
Immutep granted European patent for IMP761
October 21, 2020
Immutep reports improving results from INSIGHT-004 trial
September 17, 2020
IMM & Monash Uni receive funding grant for LAG-3 Research
August 30, 2020
Appendix 4E & 2020 Full Year Statutory Accounts
August 25, 2020
Recruitment of stage 1 of part B in TACTI-002 study complete
August 17, 2020
Immutep granted US patent for eftilagimod alpha
August 11, 2020
US patent granted for IMP701 antibody
July 14, 2020
Immutep Completes Recruitment for Part A of TACTI-002 trial
June 28, 2020
Immutep receives A$1,437,826 R&D Tax Incentive
June 21, 2020
Immutep announces improving data from TACTI-002 ph II trial
May 31, 2020
Immutep receives $3.6M R&D French tax incentive
May 28, 2020
Immutep granted Japanese patent for eftilagimod alpha
May 6, 2020
INSIGHT-004 and TACTI-002 data to be presented at ASCO
April 29, 2020
Immutep Investor Presentation
April 28, 2020
Immutep Reports Positive Phase II TACTI-002 Data
April 27, 2020
Enrollment completed for the INSIGHT-004 Study
April 21, 2020
Immutep March Quarterly Activities Report & Appendix 4C
April 20, 2020
Immutep advances its LAG-3 agonist for autoimmune diseases
April 15, 2020
Immutep presents TACTI-002 data at AACR Virtual Meeting
April 14, 2020
EOC Pharma confirms plans to advance Efti in China for MBC
April 8, 2020
Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
March 25, 2020
Immutep reports supportive efficacy data from AIPAC study
March 24, 2020
Decks
The 5 newest of 112 decks. Every deck is listed under its year.
- Investor Presentation (August 2026)
Investor deck · 30 slides · Aug 20, 2026
- Investor Presentation (February 2026)
Investor deck · 39 slides · Feb 20, 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 24 slides · Nov 27, 2025
- Investor Presentation (October 2025)
Investor deck · 37 slides · October 2025
- Jefferies Global Healthcare Conference 2025
Conference · 40 slides · Jun 2, 2025